HBs-[alpha]317ScFv recombinant protein, and coding sequence, expression carrier, and applications thereof

Abstract

The invention provides an HBs-[alpha]317ScFv recombinant protein, and a coding sequence, an expression carrier, and applications thereof. The HBs-[alpha]317ScFv recombinant protein comprises an aminoacid sequence coded by a nucleotide sequence represented by SEQ ID No.1 and an amino acid sequence coded by a nucleotide sequence represented by SEQ ID No.3. The HBs-[alpha]317ScFv recombinant proteincan prevent HBV infection, because the antigen presenting efficiency is high, the using amount of vaccines is reduced, and thus the cost is reduced. The HBs-[alpha]317ScFv recombinant protein can beused as a therapeutic vaccine and has a stronger performance on activating immune response, compared with a researched soluble non-target virus antigen.

Description

technical field [0001] The invention relates to the technical field of immunization, in particular to a HBs-α317ScFv recombinant protein, its coding sequence, expression vector and application. Background technique [0002] Hepatitis B virus (HBV) is the "culprit" of chronic hepatitis B, which can easily lead to liver cirrhosis and even liver cancer. Hepatitis B virus is generally transmitted through blood, sexual contact and mother to child in three ways, among which blood transmission is the most important way of transmission. [0003] Although preventive hepatitis B vaccines and antiviral drugs are on the market, 650,000 people worldwide still die from liver failure, cirrhosis and liver cancer caused by HBV infection every year. As a major hepatitis B country, China has about 93 million chronic HBV infections, of which about 20 million are chronic hepatitis B patients. Among patients with liver cirrhosis and liver cancer in my country, the proportions caused by HBV infe...

AI Technical Summary

Problems solved by technology

Although there is no relevant report on the delivery of vaccines targeting CD317 for the treatment of HBV, it can be speculated from known clues that this strategy is likely to activate a stronger antiviral immune response by enhancing the antigen presentation efficiency of pDCs and break the pathology of CHB patients. Immune tolerance state, suppression or even elimination of HBV

[0010] The existing therapeutic drugs mainly include interferon (IFN-α) and oral nucleoside analogs (NAs). Although they can effectively inhibit the virus, they cannot be completely cured. There are problems such as long-term medication, viral drug resistance, and easy recurrence.

The protein-based therapeutic vaccines under development, such as ABX203 (clinical phase II / III, the main components are HBs and HBc), are soluble antigens that do not have the ability to target, and are difficult to be taken up, processed and presented by pDCs cells, so , unable to break the immune tolerance state caused by the loss of pDCs cell function in CHB patients

Images